Effects of intake of royal jelly in type 2 diabetic patients

INTERVENTION: Control group: placebo 3 (1000mg) capsules daily Intervention 1: Intervention group: 3 royal jelly (1000mg) capsules daily. Intervention 2: Control group: placebo 3 (1000mg) capsules daily. Intervention group: 3 royal jelly (1000mg) capsules daily Prevention CONDITION: DIABETES MELLITUS. ; Non‐insulin‐dependent diabetes mellitus Non‐insulin‐dependent diabetes mellitus PRIMARY OUTCOME: Interleukin‐6. Timepoint: Before and after the intervention. Method of measurement: fast plasma interleukin‐6,ELISA method. Serum malondialdehyde. Timepoint: Before and after the intervention. Method of measurement: fast plasma malondialdehyde level,spectrophotometry. Total antioxidant capacity. Timepoint: Before and after the intervention. Method of measurement: plasma antioxidant activity ,FRAP method. INCLUSION CRITERIA: INCLUSION CRITERIA: confirmed diabetes type 2 based on physicians diagnosis, being volunteer or willingness to attend, no history of cardiovascular, liver or kidney diseases, not receiving insulin prior to 3 months before the trial, age between 20‐65 years old, HbA1c 6‐8%, no allergy to honey or its products, BMI between 20‐30, duration of type 2 diabetes mellitus for 5 ‐10 years, no history of smoking and alcohol drinking Exclusion criteria: cholesterol >=240mg/dl, TG>=400mg/dl, incomplete consumption of royal jelly, creation of allergy during the study period, using of any kind of food supplements, pregnancy, lactation, using of oral contraceptive pills, changing medication dosage